Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses through the sale of 12 million common units, each including common stock or pre-funded warrants and two Series C warrants. The company said net proceeds will be used for general corporate purposes and working capital, with potential additional gross proceeds of approximately $12 million if the Series C warrants are fully exercised for cash, while Aegis Capital acted as exclusive placement agent.
To view the full press release, visit https://ibn.fm/MTlef
About Sunshine Biopharma Inc.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
- K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
- PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.
Additional information is available at https://sunshinebiopharma.com/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN